Skip to main content
SpringerLink
Log in

Cushing’s Syndrome

  • Chapter
Endocrinology and Diabetes

  • 1977 Accesses

Abstract

Cushing’s syndrome is the resultant clinical phenotype consequent on chronic glucocorticoid excess. The most common cause of Cushing’s syndrome is exposure to exogenous glucocorticoids in the treatment of chronic inflammatory and malignant conditions. In contrast, endogenous Cushing’s syndrome is rare, occurring in around one to two individuals per million population a year. Untreated Cushing’s syndrome is associated with significant complications, and a 5-year mortality rate in the region of 50 %. The excess mortality relates primarily to vascular and infective causes. Early identification and appropriate diagnosis is essential to providing the patient an optimal outcome. Treatment of endogenous Cushing’s syndrome is dependent on identification of the aetiology, which may be pituitary, adrenal or ectopic. A number of tests are available for diagnosis, and identifying the aetiology, but all are subject to false positive and false negative results, placing weight upon clinical suspicion of the disease. Cushing’s syndrome should therefore be managed exclusively by individuals with extensive experience with this condition. Treatment is generally surgical and directed at the cause. Although surgery is highly successful, medical therapy where remission is not achieved can leave the physician wanting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ross EJ, Linch DC. Cushing’s syndrome–killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2(8299):646–9.

    Article  CAS  PubMed  Google Scholar 

  2. Malik KJ, Wakelin K, Dean S, Cove DH, Wood PJ. Cushing’s syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate. Ann Clin Biochem. 1996;33(Pt 3):​187–9.

    Article  PubMed  Google Scholar 

  3. Learoyd D, McElduff A. Medroxyprogesterone induced Cushing’s syndrome. Aust N Z J Med. 1990;​20(6):824–5.

    Article  CAS  PubMed  Google Scholar 

  4. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev. 1998;19(5):647–72.

    CAS  PubMed  Google Scholar 

  5. Arnaldi G, Mancini T, Tirabassi G, Trementino L, Boscaro M. Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications. J Endocrinol Invest. 2012;35(4):434–48.

    Article  CAS  PubMed  Google Scholar 

  6. Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, et al. The European registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011;165(3):383–92.

    Article  CAS  PubMed  Google Scholar 

  7. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;​93(5):1526–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(4):894–904.

    Article  CAS  PubMed  Google Scholar 

  9. Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am. 2008;37(1):151–71, xi.

    Article  PubMed  Google Scholar 

  10. Davenport C, Liew A, Doherty B, Win HH, Misran H, Hanna S, Kealy D, et al. The prevalence of adrenal incidentaloma in routine clinical practice. Endocrine. 2011;40(1):80–3.

    Article  CAS  PubMed  Google Scholar 

  11. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009;94(5):​1548–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab. 2001;86(1):117–23.

    CAS  PubMed  Google Scholar 

  13. Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing’s syndrome. Am J Med. 1952;13(5):​597–614.

    Article  CAS  PubMed  Google Scholar 

  14. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011;96(3):632–42.

    Article  CAS  PubMed  Google Scholar 

  15. Swearingen B, Biller BM, Barker 2nd FG, Katznelson L, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999;130(10):821–4.

    Article  CAS  PubMed  Google Scholar 

  16. Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3365–71.

    Article  CAS  PubMed  Google Scholar 

  17. Hermus AR, Smals AG, Swinkels LM, Huysmans DA, Pieters GF, Sweep CF, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J Clin Endocrinol Metab. 1995;80(10):2859–65.

    CAS  PubMed  Google Scholar 

  18. Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK. Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab. 2006;91(2):​447–53.

    Article  CAS  PubMed  Google Scholar 

  19. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab. 1999;84(8):2664–72.

    CAS  PubMed  Google Scholar 

  20. Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M, et al. Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013;169(5):​715–23.

    Article  CAS  PubMed  Google Scholar 

  21. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, et al. Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94(8):2743–50.

    Article  PubMed  Google Scholar 

  22. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, et al. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol. 2010;163(5):783–91.

    Article  CAS  PubMed  Google Scholar 

  23. Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, et al. Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab. 2011;96(11):3525–32.

    Article  CAS  PubMed  Google Scholar 

  24. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab. 2002;​87(8):3662–6.

    CAS  PubMed  Google Scholar 

  25. van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, Pereira AM, et al. The hypercoagulable state in Cushing’s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab. 2012;97(4):1303–10.

    Article  PubMed  Google Scholar 

  26. Lamberts SW, Klijn JG, de Quijada M, Timmermans HA, Uitterlinden P, de Jong FH, et al. The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing’s disease and Nelson’s syndrome. J Clin Endocrinol Metab. 1980;51(2):307–11.

    Article  CAS  PubMed  Google Scholar 

  27. Invitti C, De Martin M, Danesi L, Cavagnini F. Effect of injectable bromocriptine in patients with Cushing’s disease. Exp Clin Endocrinol Diabetes. 1995;103(4):​266–71.

    Article  CAS  PubMed  Google Scholar 

  28. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223–30.

    Article  CAS  PubMed  Google Scholar 

  29. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89(5):2452–62.

    Article  CAS  PubMed  Google Scholar 

  30. Bertagna X, Bertagna C, Laudat MH, Husson JM, Girard F, Luton JP. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing’s syndrome. J Clin Endocrinol Metab. 1986;63(3):639–43.

    Article  CAS  PubMed  Google Scholar 

  31. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, et al. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61(3):​536–40.

    Article  CAS  PubMed  Google Scholar 

  32. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, et al. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol. 2009;160(6):1003–10.

    Article  CAS  PubMed  Google Scholar 

  33. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C, SEISMIC Study Investigators. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039–49.

    Article  CAS  PubMed  Google Scholar 

  34. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab. 2006;91(11):4482–8.

    Article  CAS  PubMed  Google Scholar 

  35. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115–22.

    Article  CAS  PubMed  Google Scholar 

  36. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914–24.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Leeds Teaching Hospitals NHS Trust St. James’s University Hospital, Beckett Street, Leeds, West Yorkshire, LS14 3AR, UK

    Robert D. Murray BSc, MD, FRCP

Authors
  1. Robert D. Murray BSc, MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert D. Murray BSc, MD, FRCP .

Editor information

Editors and Affiliations

  1. Cardiovascular and Diabetes Research, University of Leeds, Leeds, United Kingdom

    Ramzi Ajjan

  2. Department of Endocrinology, St. James’s Hospital, Leeds, United Kingdom

    Stephen M. Orme

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Murray, R.D. (2015). Cushing’s Syndrome. In: Ajjan, R., Orme, S. (eds) Endocrinology and Diabetes. Springer, London. https://doi.org/10.1007/978-1-4471-2789-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2789-5_6

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2788-8

  • Online ISBN: 978-1-4471-2789-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation